About us

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. Xspray’s strategy is to improve the quality of life for cancer patients by launching improved PKI products with relevant medical benefits and cost effectiveness.

Xspray Pharma uses its innovative, patented HyNap-technology to develop 505(b)(2) improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs), for the treatment of cancer. The segment is the largest in oncology and the drug prices are very high.

Xspray Pharma applies a unique platform technology:

• Improves the solubility of the active ingredient
• Best-in-class for high dose strength for poorly soluble drugs
• Fully amorphous (non-infringing to many crystalline products patents)

The company´s innovative technology allows Xspray Pharma’s entry as the first competitor to today’s original drugs. Xspray Pharma’s goal is to become the leader in the development of improved versions of PKI drugs already marketed for the treatment of cancer, which numbered to 80 at the end of 2023.